{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:24:22Z","timestamp":1755037462032},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.2515\/therapie\/2011001","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T04:58:14Z","timestamp":1302152294000},"page":"39-44","source":"Crossref","is-referenced-by-count":10,"title":["Niveau de preuve du suivi th\u00e9rapeutique pharmacologique des aminosides"],"prefix":"10.1016","volume":"66","author":[{"given":"Nicolas","family":"Venisse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Boulamery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011001_bb0005","first-page":"597","article-title":"Aminoglycosides-50 years on","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011001_bb0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","article-title":"Aminoglycosides: activity and resistance","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-200948020-00001","article-title":"Therapeutic drug monitoring of aminoglycosides in neonates","volume":"48","author":"Touw","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2011001_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1525-139X.2008.00554.x","article-title":"Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?","volume":"22","author":"O\u2019Shea","year":"2009","journal-title":"Semin Dial"},{"key":"10.2515\/therapie\/2011001_bb0030","first-page":"164","article-title":"Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function","volume":"87","author":"Zaske","year":"1980","journal-title":"Surgery"},{"key":"10.2515\/therapie\/2011001_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199937040-00004","article-title":"Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly","volume":"37","author":"Triggs","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2011001_bb0040","first-page":"603","article-title":"The necessity of increased doses of amikacin in burn patients","volume":"84","author":"Zaske","year":"1978","journal-title":"Surgery"},{"key":"10.2515\/therapie\/2011001_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1008634911114","article-title":"Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis","volume":"20","author":"Touw","year":"1998","journal-title":"Pharm World Sci"},{"key":"10.2515\/therapie\/2011001_bb0050","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00134-002-1313-7","article-title":"Experience with a once-daily dosing program of aminoglycosides in critically ill patients","volume":"28","author":"Buijk","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.2515\/therapie\/2011001_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01706354","article-title":"Gentamicin volume of distribution in critically ill septic patients","volume":"16","author":"Triginer","year":"1990","journal-title":"Intensive Care Med"},{"key":"10.2515\/therapie\/2011001_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.2515\/therapie\/2011001_bb0065","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/AAC.8.1.58","article-title":"Gentamicin blood levels: a guide to nephrotoxicity","volume":"8","author":"Dahlgren","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Bertino","year":"1993","journal-title":"J Infect Dis"},{"key":"10.2515\/therapie\/2011001_bb0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1128\/AAC.8.4.434","article-title":"Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin","volume":"8","author":"Goodman","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0085","first-page":"142","article-title":"Increased burn patient survival with individualized dosages of gentamicin","volume":"91","author":"Zaske","year":"1982","journal-title":"Surgery"},{"key":"10.2515\/therapie\/2011001_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jps.2600680304","article-title":"Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost\u2013benefit analysis","volume":"68","author":"Bootman","year":"1979","journal-title":"J Pharm Sci"},{"key":"10.2515\/therapie\/2011001_bb0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/clpt.1991.86","article-title":"A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration","volume":"49","author":"Burton","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2011001_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007691-199009000-00003","article-title":"Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis","volume":"12","author":"Destache","year":"1990","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011001_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007691-199009000-00004","article-title":"Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis","volume":"12","author":"Destache","year":"1990","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011001_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011001_bb0115","first-page":"223","article-title":"Once-daily dosing of aminoglycosides. A consensus document","volume":"35","author":"Anaizi","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2011001_bb0120","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011001_bb0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-199936020-00001","article-title":"Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?","volume":"36","author":"Barclay","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2011001_bb0135","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1128\/AAC.40.9.2209","article-title":"Once-daily aminoglycoside therapy: potential ototoxicity","volume":"40","author":"Singer","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0140","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/AAC.41.4.879","article-title":"Once-daily aminoglycoside therapy: potential ototoxicity","volume":"41","author":"Kirkpatrick","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011001_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0140-6736(93)90137-6","article-title":"Once versus thrice daily gentamicin in patients with serious infections","volume":"341","author":"Prins","year":"1993","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011001_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF02113434","article-title":"Easier monitoring of aminoglycoside therapy with once-daily dosing schedules","volume":"14","author":"Prins","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.2515\/therapie\/2011001_bb0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.35.3.399","article-title":"Once-daily aminoglycoside therapy","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)70798-4","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2013the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011001_bb0170","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/AAC.40.11.2494","article-title":"Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy","volume":"40","author":"Prins","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011001_bb0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.burns.2007.11.003","article-title":"Pharmacokinetic variability of extended interval tobramycin in burn patients","volume":"34","author":"Bracco","year":"2008","journal-title":"Burns"},{"key":"10.2515\/therapie\/2011001_bb0180","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2006.04.015","article-title":"Increased amikacin dosage requirements in burn patients receiving a once-daily regimen","volume":"28","author":"Conil","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.2515\/therapie\/2011001_bb0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jac\/33.2.341","article-title":"Monitoring serum concentrations for once-daily netilmicin dosing regimens","volume":"33","author":"Blaser","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie\/2011001_bb0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","article-title":"Pharmacokinetic dosing of aminoglycosides: a controlled trial","volume":"114","author":"Bartal","year":"2003","journal-title":"Am J Med"},{"issue":"1","key":"10.2515\/therapie\/2011001_bb0195","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:41:26Z","timestamp":1554277286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0040595716307363"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}